---
title: "Pharmala Biotech Appoints Lennie Ryer to Board as Malik Slassi Resigns"
description: "Pharmala Biotech Holdings Inc. has announced a change in its Board of Directors, with Dr. Malik Slassi resigning and Lennie Ryer, CPA, CA, being appointed as a new board member. This update is part of"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275514575.md"
published_at: "2026-02-10T21:40:08.000Z"
---

# Pharmala Biotech Appoints Lennie Ryer to Board as Malik Slassi Resigns

> Pharmala Biotech Holdings Inc. has announced a change in its Board of Directors, with Dr. Malik Slassi resigning and Lennie Ryer, CPA, CA, being appointed as a new board member. This update is part of the company's ongoing governance adjustments.

Pharmala Biotech Holdings Inc. has announced changes to its Board of Directors. Dr. Malik Slassi has resigned from the board, and Lennie Ryer, CPA, CA, has been appointed as a new board member. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharmala Biotech Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652217-en) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [PMCB.US - PharmaCyte Biotech](https://longbridge.com/en/quote/PMCB.US.md)
- [PBPH.US - Portfolio Bldg Blck Wld Phrm &BtchIdxETF](https://longbridge.com/en/quote/PBPH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| BB Biotech AG proposes CHF 2.25 per share dividend | BB Biotech AG has proposed a dividend of CHF 2.25 per share for the 2025 financial year, an increase from CHF 1.80 per s | [Link](https://longbridge.com/en/news/273469604.md) |
| PharmaCyte Biotech CEO Joshua Silverman Acquires Common Shares | PharmaCyte Biotech CEO Joshua Silverman has acquired common shares of the company. The full filing is available through  | [Link](https://longbridge.com/en/news/271847803.md) |
| Kane Biotech Expands Commercial Activities in the United States \| KNBIF Stock News | Kane Biotech Inc. has signed non-exclusive distribution agreements for its revyve® Antimicrobial Wound Gel product line  | [Link](https://longbridge.com/en/news/276332084.md) |
| Cibc World Market Inc. Invests $1.22 Million in QXO, Inc. $QXO | Cibc World Market Inc. has invested $1.22 million in QXO, Inc. by acquiring 64,153 shares during Q3, as reported in its  | [Link](https://longbridge.com/en/news/276106337.md) |
| BB Biotech Benefits from Improved Market Environment | BB Biotech has reported a net profit of 578 million francs for 2025, significantly up from 76 million francs in 2024. Th | [Link](https://longbridge.com/en/news/276427224.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.